If you have been reading about drug affinity complex and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The nape and the anterior third of the body have irregular pale brown and black cross bars, the black forming rings on the neck. The upper lip is pale brown, with black lines on the sutures between the shields. The lower surface of the head is brownish white. The belly and the ventral surface of the tail are blackish.
==== Specialised mammalian serpins ==== Many mammalian serpins have been identified that share no obvious orthology with a human serpin counterpart. Examples include numerous rodent serpins (particularly some of the murine intracellular serpins) as well as the uterine serpins. The term uterine serpin refers to members of the serpin A clade that are encoded by the SERPINA14 gene. Uterine serpins are produced by the endometrium of a restricted group of mammals in the Laurasiatheria clade under the influence of progesterone or estrogen. They are probably not functional proteinase inhibitors and may function during pregnancy to inhibit maternal immune responses against the conceptus or to participate in transplacental transport.
== Applications == SFC has been used primarily for separation of chiral molecules, mainly those which required normal phase conditions. While the mobile phase is a fluid in the supercritical state, the stationary phase is packed inside columns similar to those used in liquid chromatography. Since the use of normal phase mode of chromatography remained less common, so did SFC; therefore it is now commonly used for selected chiral and achiral separations and purification in the pharmaceutical industry.
Sources: en.wikipedia.org
EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface. This stimulates ligand-induced dimerization, activating the intrinsic protein-tyrosine kinase activity of the receptor (see the second diagram). The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell – a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR – that ultimately lead to DNA synthesis and cell proliferation.
Tweezing (hairs are tweezed, or pulled out, with tweezers or with fingers) Waxing (a hot or cold layer is applied and then removed with porous strips) Sugaring (hair is removed by applying a sticky paste to the skin in the direction of hair growth and then peeling off with a porous strip) Threading (also called fatlah or khite in Arabic, or band in Persian) in which a twisted thread catches hairs as it is rolled across the skin Epilators (mechanical devices that rapidly grasp hairs and pull them out). Drugs that directly attack hair growth or inhibit the development of new hair cells. Hair growth will become less and less until it finally stops; normal depilation/epilation will be performed until that time. Hair growth will return to normal if use of product is discontinued. Products include the following: The pharmaceutical drug eflornithine hydrochloride (with the trade names Vaniqa and Follinil) inhibits the enzyme ornithine decarboxylase, preventing new hair cells from producing putrescine for stabilizing their DNA. Antiandrogens, including spironolactone, cyproterone acetate, flutamide, bicalutamide, and finasteride, can be used to reduce or eliminate unwanted body hair, such as in the treatment of hirsutism. Although effective for reducing body hair, antiandrogens have little effect on facial hair. However, slight effectiveness may be observed, such as some reduction in density/coverage and slower growth. Antiandrogens will also prevent further development of facial hair, despite only minimally affecting that which is already there.
MacDonald et al. (1990) has described four general community types. These are communities dominated by Vestimentiferan tube worms (Lamellibrachia c.f. barhami and Escarpia spp.), mytilid mussels (Seep Mytilid Ia, Ib, and III, and others), vesicomyid clams (Vesicomya cordata and Calyptogena ponderosa), and infaunal lucinid or thyasirid clams (Lucinoma sp. or Thyasira sp.). Bacterial mats are present at all sites visited to date. These faunal groups tend to display distinctive characteristics in terms of how they aggregate, the size of aggregations, the geological and chemical properties of the habitats in which they occur, and, to some degree, the heterotrophic fauna that occur with them. Many of the species found at these cold seep communities in the Gulf of Mexico are new to science and remain undescribed. Individual lamellibrachid tube worms, the longer of two taxa found at seeps, can reach lengths of 3 metres (9.8 feet) and live hundreds of years (Fisher et al., 1997; Bergquist et al., 2000). Growth rates determined from recovered marked tube worms have been variable, ranging from no growth of 13 individuals measured one year to a maximum growth of 9.6 cm/yr (3.8 in/yr) in a Lamellibrachia individual (MacDonald, 2002). Average growth rate was 2.19 cm/yr (0.86 in/yr) for the Escarpia-like species and 2.92 cm/yr (1.15 in/yr) for lamellibrachids. These are slower growth rates than those of their hydrothermal vent relatives, but Lamellibrachia individuals can reach lengths 2–3 times that of the largest known hydrothermal vent species. Individuals of Lamellibrachia sp.
During World War II, wartime manufacturing expanded urban employment for black job seekers who were historically underrepresented in Detroit's labor market as labor policies sanctioned hiring discrimination. Despite the expansion of employment available to black Detroiters, racial integration within the workplace was met with fierce opposition from Blue-collar white employees. For these white Detroiters, black employment harbored intense housing competition within Detroit's overcrowded neighborhoods in addition to crumbling the economic stability of Detroit's white middle class. Therefore, as racial integration within the workplace alluded to racially fluid neighborhoods, the white middle class engaged in residential segregation by using discriminatory behavior and policy to regulate black residential agency and accessibility to homeownership. Transitioning into the postwar period, the economic hardships of manufacturing industries, stemming from suburbanization, along with overpriced rental housing, forced urban black communities to fall on hard times, devolving into decrepit remnants of Detroit's industrial surgency and booming wartime economy. The mass migration of hopeful blacks from the Jim Crow-perpetuated racism and segregation of the South into Northern neighborhoods coupled with sluggish housing construction flooded Detroit with overpopulation, limited funding, and residential mistreatment. Black families faced large down payments, high-interest land contracts, and high maintenance costs of living facilities.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.